Nurix Therapeutics (NRIX) CSO exercises 31,333 options for common stock

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported an option exercise and corresponding stock acquisition. On 02/03/2026, Hansen exercised an employee stock option for 31,333 shares of common stock at $0.84 per share, converting the derivative position to common stock. Following this transaction, Hansen directly beneficially owns 115,005 shares of Nurix common stock, and the reported option grant is fully vested with 0 derivative securities remaining.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M		31,333	A	$0.84	115,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.84	02/03/2026		M			31,333	(1)	02/10/2026	Common Stock	31,333	$0	0	D

Explanation of Responses:

1. The option is fully vested.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nurix Therapeutics (NRIX) disclose for its Chief Scientific Officer?

The Chief Scientific Officer of Nurix Therapeutics, Gwenn Hansen, reported exercising an employee stock option for 31,333 shares of common stock at $0.84 per share. This Form 4 shows a conversion of derivative options into directly held Nurix common stock.

How many Nurix Therapeutics (NRIX) shares does CSO Gwenn Hansen own after the reported Form 4 transaction?

After the reported transaction, Chief Scientific Officer Gwenn Hansen directly beneficially owns 115,005 shares of Nurix Therapeutics common stock. This figure reflects ownership immediately following the 02/03/2026 option exercise reported on the Form 4.

What was the exercise price of the stock options exercised by Nurix Therapeutics (NRIX) CSO?

The employee stock option exercised by Nurix Therapeutics Chief Scientific Officer Gwenn Hansen had an exercise price of $0.84 per share. Exercising this option on 02/03/2026 resulted in acquiring 31,333 shares of Nurix common stock.

Did the Nurix Therapeutics (NRIX) Form 4 involve derivative securities such as stock options?

Yes. The Form 4 reports an Employee Stock Option (right to buy) that was exercised on 02/03/2026 for 31,333 underlying shares of common stock. After this transaction, the number of reported derivative securities from that option grant is 0.

What change occurred in Nurix Therapeutics (NRIX) CSO’s option holdings on 02/03/2026?

On 02/03/2026, Chief Scientific Officer Gwenn Hansen exercised an employee stock option covering 31,333 shares, fully utilizing that option grant. The filing shows 0 derivative securities remaining from this specific option, which was noted as fully vested.

What does the Form 4 footnote reveal about the Nurix Therapeutics (NRIX) option grant?

The Form 4 footnote states that “The option is fully vested.” This means the employee stock option exercised by Chief Scientific Officer Gwenn Hansen on 02/03/2026 had no remaining unvested portion at the time of exercise.